Active substanceAcetylcarnitineAcetylcarnitine
Similar drugsTo uncover
  • Karniteks
    capsules inwards 
  • Carnitine®
    capsules inwards 
    PIK-PHARMA, LLC     Russia
  • Dosage form: & nbspcapsules
    Composition:

    1 capsule contains:

    Active substance: acetylcarnitine hydrochloride 295.0 mg (corresponding to 250.0 mg acetylcarnitine);

    Excipients: microcrystalline cellulose 38.0 mg, silicon colloidal dioxide (Aerosil A-300) 5.0 mg, magnesium stearate 2.0 mg; Hard gelatin capsules №0 (composition of capsules: titanium dioxide 2%, gelatin up to 100%).

    Description:

    Hard gelatin capsules № 0 of white color.

    The contents of the capsules are white to white powder with a yellowish hue of color with a faint smell of acetic acid.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    N.06.B.X   Other psychostimulants and nootropic drugs

    Pharmacodynamics:

    Acetyl-L-carnitine (ALA), a natural biologically active substance, physiologically present in the body in various organs and tissues, including the central nervous system, is involved in the metabolism of fatty acids and carbohydrates. The pharmacological and biological effects of ALA are largely due to metabolic effects L- carnitine and the acetyl group included in its composition. Acetyl-L-carnitine (ALA), a biologically active form of L-carnitine, a key substance in the process of fat catabolism and energy production in the body.ALA is synthesized in the brain tissue, liver and kidneys from L-carnitine with the participation of the enzyme carnitine acetyltransferase. Because ALA supplies activated acetate directly to the mitochondrial matrix for education acetyl-CoA, participating in the cycle of tricarboxylic acids, without additional expenditure of energy, it is an easily accessible substrate for the initiation of volatile metabolic processes in the mitochondria. Due to the high-grade energy supply of the body with less oxygen consumption by tissues, ALA protects brain tissue from ischemia.

    Due to its structural similarity with acetylcholine, ALA has a cholinomimetic effect, and also exhibits neuroprotective properties. It increases the cellular concentration of aspartic and glutamic acid, as well as taurine, with prolonged use increases the density of H-methyl-O-aspartate receptors in the hippocampus, cortex and striatum and prevents their Density under aging. ALA enhances the effects of serotonin, and also protects brain cells from the neurotoxic effects of ammonia and glutamate.

    The results of experimental studies have shown that ALA has antiamnestic activity, the ability to improve learning processes, the indices of non-associative memory, to have a positive effect on mnestic functions in the experimental model of Alzheimer's disease without causing side effects of a sedative and miorelaxing nature.

    ALA increases energy production, being an easily accessible substrate for the initiation of volatile metabolic processes in the mitochondria. Stimulates the synthesis of proteins and phospholipids to build membranes, improves regeneration processes. When pathology has a neuroprotective effect, especially in relation to neurons and their organelles (mitochondria), as well as neurotrophic action due to modulation of the activity of the nerve growth factor (NGF). It has antioxidant and membrane stabilizing action. ALA can accelerate the regeneration of nerve cells in traumatic and endocrine lesions of peripheral nerves in experimental models of polyneuropathy in diabetes.

    The noticeable effect of ALA has on the slowing down of aging processes due to the enhancement transport of fatty acids in mitochondria and maintenance of their work at the level of the young organism. ALA can accelerate the regeneration of nerve cells in traumatic and endocrine damage to peripheral nerves in experimental models of diabetes.

    Pharmacokinetics:

    In animal studies for oral administration (500 mg / kg) the maximum concentration of the drug in the blood comes in 4 hours and is 40 μM / L for 8 hours. Absorption of ALA from the gastrointestinal tract occurs due to active transport or by simple diffusion through the mucous membrane (under condition of its high concentration). In most tissues, including cerebral, ALA comes from the bloodstream (the exception is the liver and small intestine) unchanged. In the cell ALA comes through a direct volatile process against the concentration gradient. It is excreted from the body by the kidneys.

    Indications:

    - Initial dementia of the Alzheimer's type (Alzheimer's disease) and cerebrovascular dementia;

    - Peripheral neuropathy of various etiologies;

    - Primary and secondary involutionary syndromes on the background of vascular encephalopathies;

    - Decreased mental performance, to improve concentration and memory.

    Contraindications:

    - Individual hypersensitivity to the drug;

    - Age to 18 years (effectiveness and safety not established).

    Pregnancy and lactation:

    Special studies on the possibility of use during pregnancy and during breastfeeding were not conducted; apply only if the intended benefit to the mother exceeds the risk to the fetus. For the duration of treatment, breastfeeding should be discontinued.

    Dosing and Administration:

    Carnitine is taken internally. A single dose for adults is usually 1-4 capsules, a daily dose of 6-12 capsules. The course of treatment - 1-4 months.

    Side effects:Allergic reactions are possible; nausea, heartburn.
    Overdose:

    Cases of overdose are not registered.

    Interaction:No cases of drug interaction were noted.
    Form release / dosage:

    Capsules 295 mg.

    Packaging:

    For 10 or 15 capsules in a contour mesh box made of a polyvinylchloride film and aluminum foil. 6 contour cell packs of 10 capsules or 4 contour packs of 15 capsules together with instructions for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:2 years. Do not use after expiry date.
    Terms of leave from pharmacies:On prescription
    Registration number:LSR-000167/08
    Date of registration:23.01.2008
    The owner of the registration certificate:PIK-PHARMA, LLC PIK-PHARMA, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.12.2017
    Illustrated instructions
      Instructions
      Up